☰

Raedun L. Clarke, Ph.D. - Publications

Affiliations: 
2007 University of Colorado Anschutz Medical Campus, Denver, Aurora, CO 
Area:
Immunology, Microbiology Biology
Tree Info Similar researchers PubMed Report error

20 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 van der Stegen SJC, Lindenbergh PL, Petrovic RM, Xie H, Diop MP, Alexeeva V, Shi Y, Mansilla-Soto J, Hamieh M, Eyquem J, Cabriolu A, Wang X, Abujarour R, Lee T, Clarke R, et al. Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells. Nature Biomedical Engineering. PMID 35941192 DOI: 10.1038/s41551-022-00915-0  0.304
2020 Mandal M, Clarke R, Stegen Svd, Chang C, Lai Y, Witty A, Husain M, Wu C, Yang B, Dufaud C, Hsia G, Shaked H, Stokely L, Chu H, Pribadi M, et al. Abstract 3245: FT819 path to IND: First-of-kind off-the-shelf CAR19 T-cell for B cell malignancies Immunology. DOI: 10.1158/1538-7445.Am2020-3245  0.363
2019 Chang C, Van Der Stegen S, Mili M, Clarke R, Lai Y, Witty A, Lindenbergh P, Yang B, Husain M, Shaked H, Groff B, Stokely L, Abujarour R, Lee T, Chu H, et al. FT819: Translation of Off-the-Shelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical Trial Blood. 134: 4434-4434. DOI: 10.1182/Blood-2019-130584  0.531
2019 Abujarour R, Lai Y, Pribadi M, Lee T, Robinson M, Ruller C, Stegen SVd, Wang X, Stefanski J, Zhen J, Dinella J, Bonello G, Huffman J, Chu H, Clarke R, et al. Abstract LB-073: Generation of novel single cell-derived engineered master pluripotent cell line as a renewable source for off-the-shelf TCR-less CAR T cells in support of first-of-kind clinical trial Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-073  0.44
2018 Clarke R, Van Der Stegen S, Chang C, Husain M, Lai Y, Peralta E, Stokely L, Abujarour R, Dinella J, Lee T, Pribadi M, Chu H, Truong C, Sabouri-Ghomi M, Meza M, et al. Pluripotent Cell-Derived Off-the-Shelf TCR-Less CAR-Targeted Cytotoxic T Cell Therapeutic for the Allogeneic Treatment of B Cell Malignancies Blood. 132: 4546-4546. DOI: 10.1182/Blood-2018-99-116843  0.575
2018 Clarke RL, Stegen Svd, Lee T, Mansilla-Soto J, Chang C, Sasaki J, Husain M, Peralta E, Hardy I, Ortiz E, Riviere I, Sadelain M, Valamehr B. Abstract LB-108: Generation of off-the-shelf TCR-less CAR-targeted cytotoxic T cells from renewable pluripotent cells for cancer immunotherapy Immunology. 78. DOI: 10.1158/1538-7445.Am2018-Lb-108  0.537
2018 Bjordahl R, Mahmood S, Gaidarova S, Abujarour R, Clarke R, Stokely L, Rogers P, Ge M, Robinson M, Rezner B, Lee TT, Valamehr B. Abstract 3576: FT500, an off-the-shelf NK cell cancer immunotherapy derived from a master pluripotent cell line, enhances T-cell activation and recruitment to overcome checkpoint blockade resistance Cancer Research. 78: 3576-3576. DOI: 10.1158/1538-7445.Am2018-3576  0.41
2017 Cichocki F, Bjordahl R, Gaidarova S, Rogers P, Clarke R, Groff B, Moreno S, Abujarour R, Robinson M, Bonello G, Lee T, Lan W, Rezner B, Abbot S, Sumstad D, et al. Clinical Translation of Pluripotent Cell-Derived Off-the-Shelf Natural Killer Cell Cancer Immunotherapy Blood. 130: 656-656. DOI: 10.1182/Blood.V130.Suppl_1.656.656  0.47
2017 Bjordahl R, Clarke R, Gaidarova S, Bauer M, Sasaki J, Groff B, Lee T, Lan W, Abujarour R, Bonello G, Robinson M, Hardy I, Shoemaker D, Valamehr B. Multi-Functional Genetic Engineering of Pluripotent Cell Lines for Universal Off-the-Shelf Natural Killer Cell Cancer Immunotherapy Blood. 130: 3187-3187. DOI: 10.1182/Blood.V130.Suppl_1.3187.3187  0.473
2017 Stegen SVD, Clarke R, Soto JM, Ortiz E, Chang C, Sasaki J, Lee T, Lan W, Shoemaker D, Riviere I, Valamehr B, Sadelain M. Generation of Clonal Antigen Specific CD8αβ+ Cytotoxic T Lymphocytes from Renewable Pluripotent Stem Cells for Off-the-Shelf T Cell Therapeutics Blood. 130: 163-163. DOI: 10.1182/Blood.V130.Suppl_1.163.163  0.549
2017 Bjordahl R, Cichocki F, Clarke R, Gaidarova S, Groff B, Rogers P, Moreno S, Abujarour R, Bonello G, Lee T, Lan W, Bauer M, Robbins D, Rezner B, Cooley S, et al. Abstract 3755: Renewable and genetically engineered natural killer cells for off-the-shelf adoptive cellular immunotherapy Cancer Research. 77: 3755-3755. DOI: 10.1158/1538-7445.Am2017-3755  0.499
2016 Abujarour R, Lan W, Lee TT, Bonello G, Meza M, Robinson M, Clarke R, Truong C, Lynn C, Robbins D, Rezner B, Abbot SE, Shoemaker D, Valamehr B. Efficient Site-Specific Multi-Gene Engineering of Renewable Pluripotent Cells for Generation of Off-the-Shelf Hematopoietic Immunotherapeutics Blood. 128: 5887-5887. DOI: 10.1182/Blood.V128.22.5887.5887  0.424
2016 Bjordahl R, Clarke R, Gaidarova S, Groff B, Rogers P, Moreno S, Abujarour R, Bonello G, Lee TT, Lan W, Burrascano M, Bauer M, Robinson M, Sasaki J, Kim W, et al. Off-the-Shelf Natural Killer Cell Immunotherapy for Enhanced Antibody Directed Cellular Cytotoxicity Blood. 128: 3363-3363. DOI: 10.1182/Blood.V128.22.3363.3363  0.515
2016 Bauer M, Clarke R, Sasaki J, Groff B, Lee TT, Lan W, Abujarour R, Bonello G, Burrascano M, Robinson M, Bjordahl R, Gaidarova S, Abbot SE, Wolchko S, Shoemaker D, et al. Genetic Engineering of Pluripotent Cells for the Continuous Derivation of Off-the-Shelf Effector Lymphocytes with Enhanced Therapeutic Persistence By Overcoming the Host Histocompatibility Barrier Blood. 128: 2165-2165. DOI: 10.1182/Blood.V128.22.2165.2165  0.416
2016 Clarke R, Groff B, Sasaki J, Bauer M, Lee TT, Lan W, Burrascano M, Abujarour R, Bonello G, Robinson M, Foster H, Robbins D, Wolchko S, Shoemaker D, Abbot SE, et al. Genetically Enhanced Pluripotent Stem Cell-Derived T Lymphocytes for Off-the-Shelf Cellular Immunotherapy Blood. 128: 2164-2164. DOI: 10.1182/Blood.V128.22.2164.2164  0.467
2015 Huang X, Lan W, Parone P, Clarke R, Abujarour R, Robinson M, Meza M, Raynel S, Rezner B, Robbins D, Lee TT, Shoemaker D, Valamehr B. Human Induced Pluripotent Stem Cells Incorporating Safe Harbor Loci Integrated Inducible Suicide Systems for Use in the Application of Cellular Therapeutics Blood. 126: 3237-3237. DOI: 10.1182/Blood.V126.23.3237.3237  0.402
2015 Clarke R, Kim W, Groff B, Abujarour R, Robinson M, Huang X, Sahaf N, Raynel S, Rezner B, Robbins D, Guerrettaz L, Shoemaker D, Valamehr B. A Platform for the Scalable Derivation of Genetically-Enhanced T and NK Lymphocytes from Naive Human Induced Pluripotent Stem Cells for Cancer Immunotherapy Blood. 126: 2364-2364. DOI: 10.1182/Blood.V126.23.2364.2364  0.434
2009 Clarke RL, Thiemann S, Refaeli Y, Werlen G, Potter TA. A new function for LAT and CD8 during CD8-mediated apoptosis that is independent of TCR signal transduction. European Journal of Immunology. 39: 1619-31. PMID 19449311 DOI: 10.1002/Eji.200839062  0.643
2009 Young RM, Hardy IR, Clarke RL, Lundy N, Pine P, Turner BC, Potter TA, Refaeli Y. Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. Blood. 113: 2508-16. PMID 18981293 DOI: 10.1182/Blood-2008-05-158618  0.542
2004 Grebe KM, Clarke RL, Potter TA. Ligation of CD8 leads to apoptosis of thymocytes that have not undergone positive selection. Proceedings of the National Academy of Sciences of the United States of America. 101: 10410-5. PMID 15232005 DOI: 10.1073/Pnas.0402079101  0.571
Show low-probability matches.